Sermorelin
GHRH (1-29)
Sermorelin is a growth-hormone-releasing hormone (GHRH) analog — the peptide that's been the gentle, well-studied entry point to GH-axis support for decades. It nudges your own pituitary to release growth hormone in a natural rhythm, and it even has an FDA-approval history. This guide covers how sermorelin works, what the research shows, dosing references, safety and its current regulatory status.
Sermorelin quick facts
| Reported research dosing | 100mcg-500mcg |
| Route | Subq |
| Cycle length | 3-6 Months |
| Frequency | 1-2x Daily AM/PM · 5 On 2 Off or Daily |
| Half-life | ~10–20 min |
| Forms | Injectable |
| Evidence level | Human (was FDA-approved) |
The entry-level GHRH. Solid, mild, well-tolerated.
How sermorelin works
Sermorelin is a synthetic GHRH (1-29) analog — it's the first 29 amino acids of growth-hormone-releasing hormone, which research showed is the portion needed for full activity at the GHRH receptor. It binds those receptors on the pituitary and triggers a pulse of your own growth hormone. Its very short half-life (about 11–12 minutes) is actually a feature: it prompts a pulse and clears out fast, leaving your body's natural GH rhythm intact rather than overriding it.
What the research & clinical use show
Sermorelin has a real clinical history — it was FDA-approved in 1997 (as Geref) to treat childhood growth-hormone deficiency. Today it's discussed in adult wellness and longevity medicine for goals like energy, sleep quality, body composition and recovery. The honest caveat: strong evidence for clinical benefit in otherwise-healthy aging adults is limited, even though the mechanism is plausible and it's generally considered a gentle option.
Sermorelin dosing (research reference)
Most protocols in the literature reference 200–300 mcg once nightly, subcutaneously, about 30–60 minutes before bed on an empty stomach — timed to ride along with the body's largest natural GH pulse during early sleep. It's reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. This summarizes existing references for education only, not dosing advice.
Safety & side effects
Sermorelin is generally considered one of the gentler GH-axis peptides, with injection-site reactions and flushing among the more common minor effects. The important caution applies to the whole class: it works by raising GH and IGF-1, and elevated IGF-1 has been associated with increased risk of certain cancers and can promote the growth of existing tumors. That's a real reason it warrants professional oversight rather than casual use.
Sermorelin vs the other GH options
Sermorelin (GHRH 1-29) is the classic gentle GHRH. Tesamorelin is a stronger, FDA-approved GHRH analog aimed at visceral fat. The CJC-1295 + Ipamorelin stack pairs a longer-acting GHRH with a GHRP for a bigger pulse, and MK-677 is the oral option. Sermorelin's appeal is its simplicity, short physiologic pulse, and track record.
Legal & regulatory status
Sermorelin is not currently a marketed FDA-approved drug (the original approval was discontinued in 2008 for commercial reasons), but as of 2026 it sits in FDA 503A Category 1, meaning licensed compounding pharmacies can legally prepare it. GH secretagogues are also banned in competitive sport under WADA. Follow the laws that apply to you.
✅ Clinically validated
- Was FDA-approved (as Geref) for paediatric growth-hormone deficiency and used as a diagnostic agent for GH reserve, so the human pharmacology is properly characterised. It was withdrawn commercially rather than for safety — a business decision, which is a distinction worth knowing.
📊 Correlative data
- Two decades of use in anti-ageing and hormone clinics, almost all of it unpublished. The consistent clinical observation is better sleep quality within weeks and body-composition change over months, in that order.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 Theoretical / extrapolated
- A GHRH fragment (1–29), so the same pituitary-level mechanism as tesamorelin with a much shorter half-life. The short action predicts what users report: a sharp pulse that suits bedtime dosing, and tolerance if you dose it too often to let the axis reset.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Sermorelin — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Fasted — and pre-bed is the best of the windows
Food is the problem here, and specifically carbohydrate and fat. Both trigger somatostatin release, and somatostatin is the brake on growth hormone — eating before the injection pharmacologically cancels it. Two clear hours either side.
Pre-bed is the strongest window because the largest natural GH pulse happens in the first hours of deep sleep, so you are stacking with it rather than asking the pituitary for something it is not primed for. Fasted pre-training is the second-best, for the same reason in a different rhythm.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Sermorelin reconstitution calculator
Research reconstitution calculator
Where to get Sermorelin
Buy Sermorelin at Flawless Compounds →Sermorelin — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Sermorelin moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Sermorelin — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
Bloodwork to run alongside Sermorelin
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | The dosing target — feel is not a measurement |
| Fasting Insulin | The insulin trade that comes with every secretagogue |
| HbA1c (Hemoglobin A1c) | Three-month confirmation |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose and organ baseline |
The Running GH Peptides or MK-677 panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 102 markers A–Z
Sermorelin — frequently asked questions
What is sermorelin?
Sermorelin is a synthetic GHRH (1-29) analog that prompts your pituitary to release your own growth hormone in a natural pulse. It has an FDA-approval history and is considered a gentle GH-axis option.
How does sermorelin work?
It binds GHRH receptors on the pituitary to trigger a GH pulse, then clears fast (~11–12 minute half-life), preserving your natural GH rhythm rather than overriding it like injected HGH.
How is sermorelin dosed?
The literature commonly references 200–300 mcg once nightly, subcutaneously, ~30–60 minutes before bed on an empty stomach to align with the natural nighttime GH pulse. Reconstituted with bacteriostatic water (see calculator). This is educational, not dosing advice.
Is sermorelin FDA-approved?
Not currently as a marketed drug — the original approval (Geref) was discontinued in 2008. But it sits in FDA 503A Category 1, so compounding pharmacies can legally prepare it.
What are the side effects of sermorelin?
Usually mild — injection-site reactions and flushing. The class-wide caution is that raising GH/IGF-1 has been linked to certain cancer risks and can promote existing tumors, so it warrants professional oversight.
Sermorelin vs CJC-1295 / Ipamorelin?
Sermorelin is a simple, gentle, short-acting GHRH. CJC-1295 + Ipamorelin pairs a longer-acting GHRH with a GHRP for a larger, synergistic pulse. Different intensity, same GH axis.
References & further reading
- Sermorelin: how it works, safety and access (Testing.com)
- Sermorelin research profile & guide (Peptides Institute)
- Sermorelin: complete guide to the GHRH (1-29) analog
Want Coach Cam's exact Sermorelin protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Sermorelin is used for
Sermorelin appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.